Psilocybin Case Study with Positive Outcomes

Oceanside Treatment Center Bahamas Clinical Case Study on Psilocybin Assisted Treatment to Treat Moderate and Severe Depression and Anxiety

This Study was sought to examine the efficiency and safety of psilocybin through 12 months.

Oceanside Treatment Center Bahamas conducted a 12-month clinical psilocybin case study on its participants Jan 2, 2021, to Dec. Dec. 29, 2021.  The study design consisted of 24 participants ages 25 to 60 with a clinical diagnosis of moderate to severe depression with a dual diagnosis of anxiety.  Participants were closely medically and psychologically screened with baseline assessments by our facilitators and our medical team. 

Study Design

Participants entered into the preparation period 2 weeks prior to treatment.  During this period, they received 8 to10 hours total of preparation meetings with two facilitators and a psychologist.

After each participant completed their prep sessions, they started their treatment. On week one they received psilocybin 20 mg/kg. 7 days later they received psilocybin 30 mg/kg.  Each treatment session lasted 6-8 hours and was conducted by a licensed therapist, registered nurse and medical physician.  Participants returned for follow up integration sessions for one week for processing and analysis of treatment experience.  Follow up care questionnaires via teleconference or zoom at 1, 3, 6, and 12 months.

Measures of Depression

Methods

The Primary outcome measure was the GRID-HAMD (Depression Rating Scale Standardization). Self-Report Questionnaires (QIDS) Quick Inventory of Depressive Symptoms and the Beck Depression Inventory (BDI), and the Anxiety Symptoms Questionnaire (ASQ).  Depression and Anxiety severity was assessed at baseline and at each of the follow-up time dates.

Participants acute psilocybin outcomes

Participants rated their experience using a measuring scale (AIQ20) at each therapy session within one month of treatment. The results in percentage to how the participants experienced an increase in improvement of categories:

Spiritually Significant: 82%  

Personal Meaning: 90%  

Deep Personal Experience:  95% 

Transformational Experience:  88% 

Improvement of Depression:  92% 

Measure of Anxiety:  83%

General Improvement of Wellbeing: 95% 

Participants Overall Well-being

At 1-, 3-, 6-, and 12-months follow-ups 

Methods

Participants rated their overall well-being on a scale (AIQ10) and measured an overall well-being score 10- (AIWBS).  The score was calculated on a 10-point scale using subcategories. The scale was implemented at each follow-up point.

Decrease in Depression:  85%

Decrease in Anxiety:  78%

Positive change in life:  90%

Better mood and balance:  77%

Better sense of self:  82%

Better understanding of life:  68% 

Positive changes in behavior:  88%

More Spiritual life:  90%

Personal Meaning:  86%

Overall, Health and Wellness:  93% 

Results and Conclusion

All 24 participants attended and completed all follow up visits thru the 12-month time point. There were no serious adverse effects during the psilocybin treatment doses and or after the 12-month time point. 

These findings demonstrate substantial antidepressant effects and anti-anxiety effects of psilocybin assisted therapy following acute intervention in a 12-month period of time following treatment.